MedTrace Logo

Cytisine Versus Varenicline for Smoking Cessation

NCT02957786 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 679

Last updated 2021-08-19

No results posted yet for this study

Summary

To evaluate the effectiveness, safety, and cost-effectiveness of cytisine plus behavioural support compared to varenicline plus behavioural support for smoking cessation, in indigenous Māori (or family of Māori) who smoke and are motivated to quit.

Conditions

  • Smoking Cessation

Interventions

DRUG

Cytisine

Cytisine tablets

BEHAVIORAL

Behavioural support

Withdrawal-orientated cessation support

DRUG

Varenicline

Varenicline tablets

Sponsors & Collaborators

  • Lakes District Health Board

    collaborator OTHER

  • Brunel University

    collaborator OTHER

  • University of Auckland, New Zealand

    lead OTHER

Principal Investigators

  • Natalie Walker, PhD · University of Auckland, New Zealand

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-18
Primary Completion
2019-10-10
Completion
2019-10-10

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02957786 on ClinicalTrials.gov